AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.220

0.000

Volume:272.99K

Turnover:59.34K

Market Cap:132.09M

PE:-4.43

High:0.220

Open:0.215

Low:0.215

Close:0.220

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.48

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-8.95

PE(LYR):-4.43

Loading ...

Overview Company News Filings

Concept

Novel Coronavirus Treatment+0.74%

Pharmaceutical Companies-0.09%

Capital Flow

Inflow:

Outflow:

News

Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%

MT Newswires Live

Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility

MT Newswires Live

Dimerix Ltd-Waiver of Listing Rule 10.1 Granted

THOMSON REUTERS

Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigrwd.com/stock/DXB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.22,"timestamp":1791868320000,"preClose":0.22,"halted":0,"volume":272987,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Closed","change":0,"latestTime":"10-13 16:12:00 AEDT","open":0.215,"high":0.22,"low":0.215,"amount":59335,"amplitude":0.022727,"askPrice":0.22,"askSize":110413,"bidPrice":0.21,"bidSize":170294,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.22,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":0.484802,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.22,"auctionPrice":0.22,"auctionVolume":20356,"auctionTime":1791868199860,"referencePrice":0.22,"referenceTime":1791887404086,"auction":3,"marketStatus":"盘后竞价","timestamp":1791868199860}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.484802,"shares":600396776,"dividePrice":0,"high":0.22,"amplitude":0.022727,"preClose":0.22,"low":0.215,"week52Low":0.157,"pbRate":"-8.95","psRate":"20.79","week52High":0.665,"institutionHeld":0,"latestPrice":0.22,"committee":0.213322,"eps":-0.0497,"divideRate":0,"volume":272987,"delay":0,"ttmEps":-0.0497,"open":0.215,"prevYearClose":0.55,"prevWeekClose":0.22,"prevMonthClose":0.23,"prevQuarterClose":0.23,"fiveDayClose":0.23,"twentyDayClose":0.235,"sixtyDayClose":0.23,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673774180","title":"Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673774180","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673774180?lang=en_us&edition=fundamental","pubTime":"2026-10-05 11:13","pubTimestamp":1791170020,"startTime":"0","endTime":"0","summary":"Dimerix  said the first patient successfully completed two years in an open label extension study of DMX-200 for the potential treatment of focal segmental glomerulosclerosis, a life-threatening kidney disease, in addition to two years in the Action3 phase 3 trial, according to a Monday filing with the Australian bourse.The open label extension study allows patients who complete a phase three clinical trial to receive DMX-200 for up to two years regardless of whether they received DMX-200 or placebo during the blinded phase of the trial.The phase three trial remains ongoing with the adult group fully recruited, and patients who complete the open label extension study will be offered continued access to DMX-200 once ethics approval for a post-trial-access scheme is obtained, Dimerix said.It added that more than 90% of eligible patients who completed the phase three trial have elected to continue into the two-year open label study, data from which could support future regulatory and comm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","DMX","DXB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669736001","title":"Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2669736001","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669736001?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:17","pubTimestamp":1790122651,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed that it completed an initial drawdown under its AU$34 million non-dilutive funding facility, receiving gross proceeds of AU$17 million, according to a Wednesday Australian bourse filing.The remaining AU$17 million is available for drawdown at the firm's election until March 31, 2027, subject to facility terms, the company said.It also confirmed that it was funded through to the delivery of the Action3 phase three trial of its DMX-200 treatment candidate in patients with focal segmental glomerulosclerosis, a rare kidney disease, and continued advancement of the phase two trial of DMX-652 in acute kidney injury.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115427","title":"Dimerix Ltd-Waiver of Listing Rule 10.1 Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115427?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115404","title":"Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115404?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DXB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":0.007428},{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.000924}]}}